Accessibility StatementSkip Navigation BRANFORD, Conn., Nov. 12, 2025 /PRNewswire/ -- Azitra, Inc. ("Azitra") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the quarter ended September 30, 2025, and provided a business update. Q3 2025 and Recent Business Highlights About Azitra, Inc. Azitra, Inc. is a clinical stage biopharmaceutical company focused on developing innovative therapie ...